X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
folfiri (488) 488
index medicus (451) 451
oncology (443) 443
humans (399) 399
colorectal cancer (366) 366
chemotherapy (329) 329
colorectal neoplasms - drug therapy (281) 281
female (271) 271
bevacizumab (269) 269
male (268) 268
middle aged (255) 255
aged (249) 249
antineoplastic combined chemotherapy protocols - therapeutic use (245) 245
leucovorin (244) 244
fluorouracil (242) 242
camptothecin - analogs & derivatives (231) 231
colorectal neoplasms - pathology (229) 229
irinotecan (220) 220
oxaliplatin (220) 220
1st-line treatment (217) 217
adult (201) 201
cancer (199) 199
metastasis (192) 192
treatment outcome (169) 169
camptothecin - administration & dosage (166) 166
fluorouracil - administration & dosage (166) 166
cetuximab (156) 156
leucovorin - administration & dosage (147) 147
neoplasm metastasis (132) 132
antineoplastic combined chemotherapy protocols - adverse effects (126) 126
metastatic colorectal cancer (118) 118
disease-free survival (116) 116
antineoplastic combined chemotherapy protocols - administration & dosage (111) 111
care and treatment (109) 109
open-label (107) 107
survival (104) 104
therapy (104) 104
folfiri plus bevacizumab (100) 100
folfox (96) 96
aged, 80 and over (92) 92
camptothecin - therapeutic use (86) 86
colorectal neoplasms - mortality (84) 84
combination (84) 84
trial (84) 84
camptothecin - adverse effects (82) 82
organoplatinum compounds - administration & dosage (82) 82
medicine & public health (80) 80
fluorouracil - therapeutic use (79) 79
5-fluorouracil (75) 75
pharmacology & pharmacy (75) 75
drug therapy (74) 74
leucovorin - therapeutic use (74) 74
fluorouracil - adverse effects (73) 73
panitumumab (72) 72
research (72) 72
colorectal neoplasms - genetics (70) 70
randomized-trial (69) 69
retrospective studies (69) 69
survival rate (69) 69
leucovorin - adverse effects (68) 68
liver neoplasms - secondary (66) 66
patients (66) 66
prognosis (65) 65
phase-iii (64) 64
analysis (62) 62
metastases (60) 60
tumors (60) 60
hematology, oncology and palliative medicine (59) 59
antineoplastic agents (58) 58
cancer therapies (58) 58
clinical trials (58) 58
colorectal carcinoma (58) 58
antimitotic agents (54) 54
kaplan-meier estimate (54) 54
antineoplastic agents - therapeutic use (53) 53
multicenter (53) 53
antibodies, monoclonal - administration & dosage (51) 51
cancer patients (51) 51
adenocarcinoma - drug therapy (50) 50
antibodies, monoclonal, humanized - administration & dosage (50) 50
liver neoplasms - drug therapy (50) 50
capecitabine (49) 49
kras (49) 49
phase-iii trial (48) 48
neoplasm staging (47) 47
efficacy (46) 46
surgery (46) 46
internal medicine (43) 43
cancer research (42) 42
metastatic colorectal-cancer (42) 42
phase-ii (42) 42
ras mutations (42) 42
young adult (41) 41
randomized phase-iii (40) 40
infusional fluorouracil (39) 39
mutation (39) 39
plus irinotecan (39) 39
organoplatinum compounds - therapeutic use (38) 38
toxicity (37) 37
gastroenterology and hepatology (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (665) 665
Japanese (17) 17
German (6) 6
Chinese (2) 2
Czech (2) 2
Hungarian (2) 2
Korean (2) 2
French (1) 1
Italian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 02/2013, Volume 40, Issue 2, pp. 249 - 253
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 05/2016, Volume 43, Issue 5, pp. 583 - 586
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 134 - 141
Purpose: MiR-31-3p expression has been shown to be associated with response to anti-EGFR therapy. We investigated the predictive role of this biomarker in the... 
SURVIVAL | FIRE-3 | ONCOLOGY | BEVACIZUMAB | FOLFIRI PLUS CETUXIMAB | OPEN-LABEL | KRAS | MICRORNA EXPRESSION | PROGRESSION
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7, pp. 674 - 681
Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer... 
NON-INFERIORITY | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | THERAPY | ONCOLOGY | IRINOTECAN | OPEN-LABEL | OXALIPLATIN | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | Life Sciences | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2018, Volume 24, Issue 16, pp. 3838 - 3844
Purpose: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study... 
CETUXIMAB | RESISTANT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED-TRIAL | MUTATIONS | FLUOROURACIL | FOLFIRI
Journal Article
by Qin, SK and Li, J and Wang, LW and Xu, JM and Cheng, Y and Bai, YX and Li, W and Xu, N and Lin, LZ and Wu, Q and Li, YF and Yang, JW and Pan, HM and Ouyang, XN and Qiu, WS and Wu, KC and Xiong, JP and Dai, GH and Liang, HJ and Hu, CH and Zhang, J and Tao, M and Yao, Q and Wang, JY and Chen, JJ and Eggleton, SP and Liu, TS
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2018, Volume 36, Issue 30, pp. 3031 - 3031
PurposeCetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectal... 
GROWTH-FACTOR RECEPTOR | BENEFIT | THERAPY | METAANALYSIS | BIOMARKER | ONCOLOGY | BRAF MUTATION | BEVACIZUMAB | IRINOTECAN | CHEMOTHERAPY | FOLFIRI | Index Medicus | ORIGINAL REPORTS
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 29 - 37
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 11/2015, Volume 42, Issue 11, pp. 1427 - 1430
Journal Article
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 7 - 15
摘要 背景 . 本研究比较瑞戈非尼与曲氟尿苷/Tipiracil(TFTD)治疗接受标准化疗无效的转移性结直肠癌(mCRC)患者的疗效, 尽管这两种药物已经获批准用于临床用途, 但尚不清楚应将哪种药物用于初始治疗。 材料与方法 .... 
Regorafenib | TAS‐102 | Propensity score | Trifluridine/tipiracil | Colorectal cancer | TAS-102 | 1ST-LINE TREATMENT | EFFICACY | BEVACIZUMAB | Trifluridine | FOLFIRI | TRIAL | CORRECT | tipiracil | CETUXIMAB | ONCOLOGY | RANDOMIZED PHASE-III | THERAPIES | Gastrointestinal Cancer
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 08/2019, Volume 37, Issue 22, pp. 1876 - 1876
To determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene... 
1ST-LINE TREATMENT | CETUXIMAB | FIRE-3 | INHIBITION | MODELS | ONCOLOGY | STATISTICS | CLASSIFICATION | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | CHEMOTHERAPY | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2018, Volume 29, Issue 7, pp. 1528 - 1534
Abstract Background Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a... 
Primary sidedness | FOLFOXIRI plus bevacizumab | RAS and BRAF mutational status | Metastatic colorectal cancer | ANTIBODIES | LOCATION | 1ST-LINE TREATMENT | DISTAL | ONCOLOGY | RAS | primary sidedness | metastatic colorectal cancer | FOLFIRI
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 01/2019, Volume 37, Issue 1, pp. 22 - 22
PurposeThe XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of... 
CAPECITABINE | 1ST-LINE TREATMENT | ONCOLOGY | EARLY TUMOR SHRINKAGE | FOLFOXIRI | PHASE-II | OPEN-LABEL | OXALIPLATIN | FOLFIRI PLUS BEVACIZUMAB | ELDERLY-PATIENTS | CHEMOTHERAPY
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 68 - 75
Abstract Background Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative... 
Hematology, Oncology and Palliative Medicine | Colorectal neoplasms | Folfox protocol | FOLFIRI protocol | Cetuximab | Gene expression profiling | Bevacizumab | SOLID TUMORS | PHASE-III | CLASSIFICATION | FOLFIRI RESPONSE | CHEMOTHERAPY | ONCOLOGY | DRUGS | GENE-EXPRESSION | Liver Neoplasms - classification | Prognosis | Adenocarcinoma - classification | Colorectal Neoplasms - genetics | Humans | Middle Aged | Transcriptome | Male | Fluorouracil - therapeutic use | Neoplasm Metastasis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Adenocarcinoma - genetics | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Survival Rate | Treatment Outcome | Colorectal Neoplasms - classification | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Antimitotic agents | Care and treatment | Cancer patients | Metastasis | Antineoplastic agents | Colorectal cancer | Gene expression | Colorectal carcinoma | Medical services | Patients | Survival | Clinical outcomes | Metastases | Studies | Irinotecan | Annotations | Colon cancer | Classification | Colon | Drug therapy | Tumors | Cancer | Index Medicus | Life Sciences
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 624 - 631
Abstract Background Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal... 
SIRB | XELOX | IRIS | FOLFOX | mCRC | THERAPY | ONCOLOGY | OXALIPLATIN | COLON | COMBINATION | CHEMOTHERAPY | FOLFIRI | Index Medicus | Original
Journal Article